Your search history is turned on.
Date: April 22, 2024 Jurisdictions: All jurisdictions
Innocan Pharma Initiates FDA Approval Process for Liposome Injection Therapy for Chronic Pain Innocan Pharma Initiates FDA Approval Process for Liposome Injection Therapy for Chronic Pain With its submission of a Pre-IND Meeting Request Letter, Innocan initiates the regulatory process with the U.S. Food and Drug Administration (FDA) for the approval of its prolonged CBD release technology for human u...
Date: April 18, 2024 Jurisdictions: All jurisdictions
Innocan Pharma Corporation Form of Proxy Annual General Special Meeting to be held on May 9, 2024 Traders Bank Building 702, 67 Yonge Street Toronto ON M5E 1J8 Appointment of Proxyholder I/We being the unde...
Innocan - Notice of Meeting INNOCAN PHARMA CORPORATION NOTICE OF ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS TO BE HELD ON MAY 9, 2024 AND MANAGEMENT INFORMATION CIRCULAR DATED APRIL 5, 2024 2 INNOCAN PHARMA CORPORATION NOTICE OF ANNUAL AND SPECIAL MEETING OF SHA...
Innocan - Notice of Meeting 2 INNOCAN PHARMA CORPORATION NOTICE OF ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS TAKE NOTICE THAT an annual and special meeting (the Meeting) of the shareholders of InnoCan Pharma Corporation (the Corporation) will be held at the offices of the Corporations solicitors Gowling WLG (Canada) LLP, 1600 100 King St. W, To...
Date: April 1, 2024 Jurisdictions: All jurisdictions
Microsoft Word - INNO - Annual CFO Cert - Mar 2024.doc Form 52-109F1 AIF Certification of annual filings in connection with voluntarily filed AIF This certificate is being filed on the same date that Innocan Pharma Corporation (the issuer) has voluntarily filed an AIF. I, Nelson Halpern, Chief Financial Officer of the issuer, certify the following: ...
Microsoft Word - INNO - Annual CEO Cert - Mar 2024.doc Form 52-109F1 AIF Certification of annual filings in connection with voluntarily filed AIF This certificate is being filed on the same date that Innocan Pharma Corporation (the issuer) has voluntarily filed an AIF. I, Iris Bincovich, Chief Executive Officer of the issuer, certify the following: ...
Microsoft Word - Innocan - Annual Information Form (2023)(61231284.5).docx Annual Information Form For the year ended December 31, 2023 Dated March 28, 2024 TABLE OF CONTENTS ABOUT THIS ANNUAL INFORMATION FORM .................................................................................. 3 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS .....
1 INNOCAN PHARMA CORPORATION Managements Discussion and Analysis For the year ended December 31, 2023 Innocan Pharma Corporation Managements Discussion and Analysis For the year ended December 31, 2023 2 1. MANAGEMENT'S ...
Date: April 1, 2024 Jurisdictions: Alberta, Ontario
Create participation fee form FORM 13-502F1 CLASS 1 AND CLASS 3B REPORTING ISSUERS PARTICIPATION FEE MANAGEMENT CERTIFICATION I, HALPERN, Nelson, an officer of the reporting issuer noted below have examined this Form 13-502F1 (the Form) being submitted hereunder to the Ontario Securities Commission and certify that to my knowledge, having exercised reasonab...
E INNOCAN PHARMA CORPORATION CONSOLIDATED FINANCIAL STATEMENTS AS OF DECEMBER 31, 2023 - 1 - INNOCAN PHARMA CORPORATION TABLE OF CONTENTS Page Independent auditor's report 2-5 Consolidated statements of financial position 6-7 C...